Efavirenz/emtricitabine/tenofovir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/960003/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/960003/Cv/1'> | ||
| - | Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains [[efavirenz]], [[emtricitabine]], and [[Tenofovir|tenofovir disoproxil]]. It can be used by itself or together with other antiretroviral medications. | + | Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains [[efavirenz]], [[emtricitabine]], and [[Tenofovir|tenofovir disoproxil]]. It can be used by itself or together with other antiretroviral medications. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) of HIV-1. Tenofovir is a nucleotide reverse transcriptase inhibitor of HIV-1, and it can be classified as an NtRTI. These three drugs work in combination to target the HIV reverse transcriptase protein in three ways, which reduces the virus's capacity to mutate. |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 07:39, 17 April 2023
| |||||||||||
